A novel neurotoxoid vaccine prevents mucosal botulism.
The threat posed by botulism, classically a food- and waterborne disease with a high morbidity and mortality, has increased exponentially in an age of bioterrorism. Because botulinum neurotoxin (BoNT) could be easily disseminated by terrorists using an aerosol or could be used to contaminate the food or water supply, the Centers for Disease Control and Prevention and the National Institute of Allergy and Infectious Diseases has classified it as a category A agent. Although clearly the development of a safe and effective mucosal vaccine against this toxin should be a high priority, essentially no studies to date have assessed mucosal immune responses to this disease. To bridge this gap in our knowledge, we immunized mice weekly for 4 wk with nasal doses of BoNT type A toxoid and a mutant of cholera toxin termed E112K. We found elevated levels of BoNT-specific IgG Abs in plasma and of secretory IgA Abs in external secretions (nasal washes, saliva, and fecal extracts). When mice given nasal BoNT vaccine were challenged with 4 x 10(3) LD50 of BoNT type A (BoNT/A) via the i.p. route, complete protection was seen, while naive mice given the same dosage died within 2 h. To further confirm the efficacy of this nasal BoNT vaccine, an oral LD50 was determined. When mice were given an oral challenge of 5 microg (2 x oral LD50) of progenitor BoNT/A, all immunized mice survived beyond 5 days, while nonimmunized mice did not. The fecal extract samples from nasally vaccinated mice were found to contain neutralizing secretory IgA Abs. Taken together, these results show that nasal BoNT/A vaccine effectively prevents mucosal BoNT intoxication.
Kobayashi
Ryoki
R
Department of Pediatric Dentistry, Immunobiology Vaccine Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Kohda
Tomoko
T
Kataoka
Kosuke
K
Ihara
Hideshi
H
Kozaki
Shunji
S
Pascual
David W
DW
Staats
Herman F
HF
Kiyono
Hiroshi
H
McGhee
Jerry R
JR
Fujihashi
Kohtaro
K
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000235:genetics; D000281:Administration, Intranasal; D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis / Q000097:blood / Q000502:physiology; D000921:Antibody-Producing Cells / Q000276:immunology / Q000378:metabolism; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000633:toxicity; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000276:immunology* / Q000633:toxicity; D001906:Botulism / Q000276:immunology / Q000517:prevention & control*; D047013:Clostridium botulinum type A / Q000276:immunology*; D007113:Immunity, Innate; D007071:Immunoglobulin A, Secretory / Q000096:biosynthesis / Q000097:blood / Q000502:physiology; D007413:Intestinal Mucosa / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009297:Nasal Mucosa / Q000276:immunology*; D014121:Toxoids / Q000008:administration & dosage / Q000276:immunology* / Q000633:toxicity
D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D007071:Immunoglobulin A, Secretory; D014121:Toxoids; D019274:Botulinum Toxins, Type A